This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.

What’s new

Patient Information Booklet for patients switching from warfarin to ELIQUIS® for stroke prevention in NVAF

ELIQUIS is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II)1

This booklet is intended only for patients prescribed ELIQUIS for the indication shown. It is not intended to replace the Patient Information Leaflet.

This booklet is intended to be read by patients only after they have been prescribed ELIQUIS. It may be read in its electronic form (PDF), or it may be printed and read.

Switching from warfarin to ELIQUIS should only be done under close clinical supervision. Any prescribing decision should only be made by the prescribing healthcare professional based on sound clinical reasons and after appropriate assessment, with patient involvement in the decision-making.

If a Patient Information booklet is printed, please ensure that:

  • It is printed in its entirety. Please do not attempt to print and use individual pages in isolation, as it has been designed to be printed in its entirety
  • Its content is not edited or altered in any way
  • It is printed in colour
  • It is printed in A4 size
  • The pages are placed in the correct order as per the page numbering

Please select the language of the Patient Information Booklet you would like to view below:

FOOTNOTES

NVAF = Non-Valvular Atrial Fibrillation   NYHA = New York Heart Association

REFERENCE

  1. ELIQUIS® (apixaban) Summary of Product Characteristics. Available at www.medicines.org.uk.